XPHYF News and Press, XPhyto Therapeutics Corp From 07/16/21

A recent study conducted by researchers from the Academy of Finland has found that almost half of all coronavirus patients who also suffer from obstructive sleep apnea need to be hospitalized. The study , which was reported in the BMJ journals, noted that moderate to acute sleep apnea pre...

Last week, the White House Office of Management and Budget published a proposal in the federal register in which it provided policy recommendations for next year’s North American Industry Classification System (“NAICS”), which is utilized in the compilation of data o...

Yet another city in California is taking steps to pass a resolution aimed at decriminalizing psychedelics. This comes after a council member from Arcata City, California, agreed to spearhead the reform effort. Last week Decriminalize Nature Humboldt revealed that Sarah Schaefer, a counci...

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience technology accelerator, recently announced that its distribution, storage and logistics partner, Max Pharma GmbH, began selling and delivering its 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”) in...

XPhyto began delivery of approximately 1,000 Covid-ID Lab test kits in Berlin This marks a significant achievement commercially, as well as for the company’s point-of-care diagnostic business strategy The lab tests are designed to offer reliable Covid-19 test results in under 2...

A recent study has found that drivers who consume marijuana may not perform or feel impaired. The study found that, instead, drivers who used marijuana would sometimes experience a positive effect on their driving. This comes at a time when policy makers are working to decide whether d...

The ongoing psychedelic renaissance has brought on a new wave of research on psychedelics, with many studies discovering the various therapeutic benefits that the substances possess. In the last 10 years, privately financed clinical studies have demonstrated the value of psychedelics in tr...

VANCOUVER, BC / ACCESSWIRE / July 2, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") announces that pursuant to its advertising agreement with AGORA Internet Relations Corp. ("AGORA") dated December 1, 2020 (the "Advertising Agreement"), the Co...

Researchers from the University of California-Davis have developed a synthetic version of ibogaine, a psychedelic drug that is nonhallucinogenic. The synthetic compound has the potential to treat various psychiatric disorders , including depression and addiction. The researchers’ fin...

XPhyto Therapeutics Corp (OTCQB: XPHYF) announced its GMP mescaline synthesis program is “on schedule” The program, which started in early 2021, is slated for completion in late Q3 2021 The first initial production batches were completed successfully, marking a significa...